ArticleResearch and practice in thrombosis and haemostasis2019
Exposure to vitamin k antagonists and kidney function decline in patients with atrial fibrillation and chronic kidney disease.
Article in Research and practice in thrombosis and haemostasis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Pooled it
- Vitamin K and women's health: a review.Frontiers in global women's health · 2025Review
- Anticoagulation in Chronic Kidney Disease.Drugs · 2024Review
- Rivaroxaban vs Vitamin K Antagonist in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease.JACC. Advances · 2024Article
- Evaluating Renal Benefits of Rivaroxaban Versus Vitamin K Antagonists in Atrial Fibrillation: A Systematic Review and Meta-analysis of Real-world Evidence.European cardiology · 2024Review
- Review
- Prescription of DOACs in Patients with Atrial Fibrillation at Different Stages of Renal Insufficiency.Advances in therapy · 2023Review
- Biological Role of Vitamin K-With Particular Emphasis on Cardiovascular and Renal Aspects.Nutrients · 2022Review
- Risk of left atrial appendage thrombus in patients with atrial fibrillation and chronic kidney disease.Cardiology journal · 2022Article
- Consequences of oral antithrombotic use in patients with chronic kidney disease.Clinical and translational science · 2021Article
- Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation.Journal of clinical medicine · 2021Review
- Non-valvular Atrial Fibrillation in CKD: Role of Vitamin K Antagonists and Direct Oral Anticoagulants. A Narrative Review.Frontiers in medicine · 2021Review
- Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation Therapy.Journal of clinical medicine · 2020Review
- Concomitant diabetes with atrial fibrillation and anticoagulation management considerations.European heart journal supplements : journal of the European Society of Cardiology · 2020Article
- The Association of dp-ucMGP with Cardiovascular Morbidity and Decreased Renal Function in Diabetic Chronic Kidney Disease.International journal of molecular sciences · 2020Article
- Real-world efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.Internal and emergency medicine · 2019Article
- Risks of anticoagulation in patients with chronic kidney disease and atrial fibrillation: More than just bleeding?Research and practice in thrombosis and haemostasis · 2019Article
- Exposure to vitamin k antagonists and kidney function decline in patients with atrial fibrillation and chronic kidney disease.Research and practice in thrombosis and haemostasis · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExposure to vitamin K antagonists (VKA) has been suggested to accelerate progression of chronic kidney disease (CKD) but robust clinical data are currently lacking.
methodsWe retrospectively evaluated the impact of VKA exposure on kidney function in patients with atrial fibrillation (AF) and CKD stage 3/4. Patients were prospectively followed within a primary care electronic database (median follow-up of 1.45 years). The kidney function trajectory over time, defined as the annualized change in estimated glomerular filtration rate (eGFR), was analyzed with linear mixed-effects regression including propensity score adjustment.
results14 432 patients (median age 78 years, median CHA
conclusionsIn patients with AF and CKD, VKA use is associated with accelerated eGFR decline. Within the limitations of a retrospective analysis, this finding supports the "VKA-renal-calcification hypothesis." However, although statistically significant, the excess loss in eGFR over 5 years with VKA was modest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.